On Jun. 11, 2021, Emergent BioSolutions announced that two batches of COVID-19 vaccine manufactured by at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and were authorized as part of Johnson & Johnsonﾒs Emergency Use Authorization (EUA).